Developing a new medication to help prevent relapse in methamphetamine users
Official title: Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse
Funded at Myosin Therapeutics INC. · NIH-10682482 · Data updated 2026-11-12
This study is testing a new medication called MT-110 to help people with methamphetamine use disorder stay off the drug and avoid relapse, since there aren't any approved treatments available right now.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Myosin Therapeutics INC. NIH-funded |
| Lab location | 1 site (Jupiter, United States) |
| Project start | September 30, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,208,298 |
| NIH project number | 5R44DA055420-03 |
| Project ID | NIH-10682482 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with methamphetamine use disorder who are seeking treatment options.
✕Less likely to help
Patients who are not struggling with methamphetamine use disorder or those who have not previously used methamphetamine may not benefit from this research.
What this research studies
This research focuses on creating a novel medication, MT-110, aimed at preventing relapse in individuals with methamphetamine use disorder. Currently, there are no FDA-approved medications for this condition, and existing behavioral therapies often fall short, leading to high relapse rates. The study investigates how MT-110, a nonmuscle myosin II inhibitor, can disrupt the motivation to seek methamphetamine, thereby supporting individuals in maintaining abstinence. The research is in the early stages, with plans to begin clinical trials soon.
Why it matters
Potential benefit: If successful, this research could provide a much-needed pharmacotherapy option for individuals struggling with methamphetamine use disorder, potentially reducing relapse rates significantly.
How similar studies have gone: While there have been various approaches to treating substance use disorders, the specific use of nonmuscle myosin II inhibitors is novel and has not been extensively tested in this context.
Where this research is happening
-
Myosin Therapeutics INC.
Jupiter, United States Active
Researchers
- Principal investigator: Young, Erica J — Myosin Therapeutics INC.
- Study coordinator: Young, Erica J
Related research
Other NIH-funded projects on the same topics.
-
Co-treated care for substance use and heart infection at UVMMC
A hospital-based project aims to improve how doctors and teams treat people with both substance use disorder and infective endocarditis during their hospital stay.
-
Genetics study of methamphetamine use disorder in Thai people
A genetics study in Thailand is looking at how genes may influence methamphetamine use disorder and related behaviors.
-
PROTECT-ED: Rapid care connects people just released from jail to HIV and overdose prevention
A program in the emergency department helps people who just left jail get started on medications for opioid use disorder and HIV prevention right away and connect them to ongoing care.
-
Justice Core: Helping pregnant women with substance use get treatment while in jail
A pragmatic trial will test whether a jail diversion program (Justice Core) improves access to treatment and perinatal outcomes for pregnant women with substance use issues compared to usual referral after jail release.
-
Adapting with Proactive SUD Intervention via Disease Intervention Specialists
A new program uses a proven outreach model to identify and connect people with substance use disorder to care earlier, by applying DIS tactics to SUD in communities.
-
ED-based Screening and Brief Intervention to Prevent Substance Use Disorder
A Purdue-led project will test if ED-based screening plus a brief in-person motivational talk and follow-up telehealth coaching can reduce risky substance use and prevent future disorder in diverse adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.